Benzinga | Sep 15, 2020 11:25AM EDT

Citigroup Maintains Buy on Sarepta Therapeutics, Raises Price Target to $190

Citigroup analyst Joel Beatty maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $177 to $190.